The Science of Predictive Proteomics in Oncology

Integrated Precision Medicine for Rational Cancer Decisions

Step 1

Analysis

Proteomic analysis of the patient’s tumor and micro-environment profile defines the tumor's specific signature.

Step 2

Proprietary Database

Specific tumor signatures from patient cohorts are collected and paired with their observed treatment response, building a foundational dataset that correlates thousands of profiles to therapy effectiveness.

Step 3

Prediction

An icon representing the BeLiver's AI engine.

BeLiver's AI model is trained on this database to understand the complex patterns of treatment response. For a new patient, the model analyzes their signature to predict a treatment response score.

Step 4

Actionable Reports

A diagram representing the predictive test results and actionable report.

Predicted responses are synthesized into an actionable report to guide personalized treatment strategies.

Why Focusing on the Proteome ?

While many approaches analyze DNA or RNA, our method uniquely studies the proteome. This layer is most directly linked to pathology because proteins are the active molecules reflecting real-time cellular biology, after all genetic and regulatory modifications have occurred.

Proteins are pivotal, as they are directly responsible for cellular biological functions and serve as the primary targets of therapeutic treatments.

By examining protein expression and the associated signaling pathways, we uncover vital insights into the mechanisms that drive treatment response, enabling a deeper understanding and more precise interventions.

An illustration of a human with his liver and a therapy targeting the liver.

A Proof-of-Concept on Liver Cancer

Our initial proof-of-concept studies in liver cancer, encompassing over 50 patients, have demonstrated success in distinguishing responders from non-responders to key systemic treatments (first- and second-line).

Building on this, we are now advancing our research through collaboration with seven leading French hospitals to validate our test for optimizing first-line treatment selection.

Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments

Delamarre et al.

2025

bioRxiv